Shares of Auris Medical Holding AG (NASDAQ:EARS) shot up 3.2% on Monday . The company traded as high as $4.26 and last traded at $4.14, with a volume of 90,302 shares changing hands. The stock had previously closed at $4.01.

A number of equities analysts have recently commented on EARS shares. Leerink Swann reissued a “buy” rating on shares of Auris Medical Holding AG in a report on Thursday, May 12th. Jefferies Group reissued a “buy” rating on shares of Auris Medical Holding AG in a report on Friday, June 10th. Finally, Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Tuesday, July 12th.

The company’s market cap is $138.35 million. The company’s 50 day moving average price is $3.96 and its 200-day moving average price is $3.95.

Auris Medical Holding AG (NASDAQ:EARS) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. During the same quarter in the prior year, the company earned ($0.28) earnings per share. Equities research analysts expect that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.